Why Tricuspid Regurgitation Is No Longer the "Forgotten" Valve Disease
For decades, the tricuspid valve was treated as an afterthought in cardiac surgery. Surgeons focused on the aortic and mitral valves — the left-sided valves that bear the brunt of high-pressure blood flow — and the tricuspid was often left alone, even when it was clearly leaking. The thinking was that tricuspid regurgitation (TR) would improve on its own once the left-sided problem was fixed.
We now know that assumption was wrong in many cases. Untreated moderate or severe tricuspid regurgitation can progress, leading to right heart failure, liver congestion, kidney dysfunction, fluid retention, and significantly reduced quality of life. Studies from the Society of Thoracic Surgeons (STS) database and major academic centers have shown that patients with significant TR who do not receive timely treatment have higher mortality rates and worse long-term outcomes.
The good news: tricuspid regurgitation treatment has advanced considerably. There are now more options — surgical and interventional — than at any point in the history of cardiac surgery. But with more options comes more complexity, and understanding what is right for your situation requires careful evaluation.
That is exactly the kind of decision where getting the right information early makes a real difference. If you have been told you have severe TR and are unsure about your next step, our free cardiac surgery risk calculator can give you a starting point for understanding your operative risk.
Understanding Tricuspid Regurgitation: Causes and Why It Matters
The tricuspid valve sits between the right atrium and right ventricle. Its job is to ensure blood flows forward into the lungs, not backward. When the valve leaks — when blood regurgitates into the right atrium — we call that tricuspid regurgitation.
Primary vs. Functional TR
There are two broad categories, and the distinction matters for treatment planning:
- Primary (organic) TR: The valve leaflets themselves are damaged. Causes include rheumatic heart disease, endocarditis, carcinoid syndrome, trauma, or congenital conditions like Ebstein's anomaly. Radiation therapy to the chest can also damage the tricuspid valve. Primary TR accounts for roughly 10-15% of significant tricuspid regurgitation cases.
- Secondary (functional) TR: The leaflets are structurally normal, but the valve leaks because the right ventricle or the tricuspid annulus (the ring of tissue the leaflets attach to) has dilated. This is far more common, representing 85-90% of cases. It is frequently caused by left-sided heart valve disease, atrial fibrillation, pulmonary hypertension, or chronic heart failure.
Why does this matter to you as a patient? Because the cause of your TR directly influences which TR repair options will work best and whether repair or replacement is the better strategy.
Grading Severity
Tricuspid regurgitation is graded by echocardiography as trace, mild, moderate, severe, or — in a newer classification gaining acceptance — massive and torrential. According to ACC/AHA guidelines, intervention should generally be considered for patients with severe or greater TR who are symptomatic, or for those with progressive right ventricular dilation even without severe symptoms.
Symptoms of significant TR often develop gradually: swelling in the legs and abdomen, fatigue, reduced exercise tolerance, a sense of fullness in the abdomen from liver congestion, and sometimes visible pulsation in the neck veins. Because these symptoms develop slowly, many patients do not realize how much their functional capacity has declined until they are evaluated formally.
Tricuspid Valve Surgery: Repair, Replacement, and Newer Interventions
When tricuspid valve surgery is indicated, there are several approaches. The choice depends on the mechanism of your TR, the condition of the valve leaflets, the size of the annulus, the function of your right ventricle, and whether you need concurrent surgery on another valve.
Tricuspid Valve Repair (Annuloplasty)
For functional TR — where the leaflets are normal but the annulus is dilated — repair with an annuloplasty ring is the most common surgical approach. The surgeon places a rigid or semi-rigid ring around the tricuspid annulus to restore its normal size and shape, allowing the leaflets to come together (coapt) properly again.
Key facts about tricuspid annuloplasty:
- It is the preferred approach whenever the leaflets are structurally intact.
- Ring annuloplasty has been shown to be more durable than suture-based (De Vega) techniques in multiple studies.
- When performed at the time of left-sided valve surgery, adding tricuspid annuloplasty increases operative time modestly but generally does not significantly increase surgical risk.
- ACC/AHA guidelines now recommend tricuspid repair at the time of left-sided valve surgery if there is severe TR, or even moderate TR with annular dilation (typically greater than 40 mm or 21 mm/m² indexed).
Tricuspid Valve Replacement
When the leaflets are severely damaged, thickened, retracted, or tethered beyond repair — as can occur with rheumatic disease, endocarditis, carcinoid, or radiation — replacement becomes necessary. This involves removing the diseased valve and sewing in a prosthetic valve.
Options include:
- Bioprosthetic (tissue) valves: Made from animal tissue (typically porcine or bovine pericardium). They do not require lifelong blood thinners (anticoagulation) but have a limited lifespan and may degenerate over 10-20 years. This is relevant if you are younger, as you may need a reoperation eventually.
- Mechanical valves: Made from synthetic materials, these are extremely durable but require lifelong warfarin therapy. They are less commonly used in the tricuspid position because the lower-pressure, lower-flow environment of the right heart increases the risk of valve thrombosis even with anticoagulation.
Reoperation on the tricuspid valve — performing surgery on a tricuspid valve that was either left alone or previously repaired — carries higher risk than a first operation. This is one reason many surgeons now advocate for addressing the tricuspid valve at the initial surgery when there is clear evidence of significant regurgitation or annular dilation.
Transcatheter (Catheter-Based) Options for TR
Just as TAVR transformed aortic valve treatment and MitraClip expanded options for mitral regurgitation, catheter-based therapies for TR are rapidly evolving. These include:
- Edge-to-edge repair (e.g., TriClip): FDA-approved in 2023, this device clips the tricuspid leaflets together to reduce regurgitation, similar in concept to MitraClip. It is performed through a vein in the leg without open-heart surgery.
- Transcatheter tricuspid valve replacement (TTVR): Several devices are in clinical trials that aim to place a new valve inside the tricuspid annulus via catheter. These are not yet widely available but represent a promising frontier.
- Annuloplasty devices and coaptation aids: Other catheter-based systems are designed to reshape the annulus or provide a surface for the leaflets to close against.
These transcatheter approaches are particularly relevant for patients who are high-risk or inoperable for traditional surgery — for example, patients with multiple prior cardiac surgeries, severe frailty, or advanced right heart failure.
However, the long-term data for these newer devices is still limited. If you have been offered a transcatheter tricuspid procedure, it is especially important to understand whether you might also be a candidate for surgical repair or replacement, which have decades of outcome data behind them. This is a scenario where a cardiac surgery second opinion can be genuinely valuable.
Timing Matters: When to Treat Tricuspid Regurgitation
One of the most consequential decisions in tricuspid regurgitation treatment is not which procedure to choose — it is when to intervene. Operating too late, after the right ventricle has failed and the liver and kidneys have been damaged by chronic congestion, dramatically increases operative risk and reduces the likelihood of a good outcome.
Current evidence supports these general principles:
- During left-sided valve surgery: If you are already undergoing mitral or aortic valve surgery and you have severe TR — or moderate TR with a dilated tricuspid annulus — the tricuspid valve should be addressed at that operation. Guidelines are clear on this, and failing to do so can lead to worsening TR that eventually requires a high-risk reoperation.
- Isolated tricuspid surgery for symptomatic severe TR: If you have severe TR with symptoms (swelling, fatigue, liver congestion) despite medical therapy, surgery should be considered before irreversible right ventricular dysfunction develops. Studies have shown that operative mortality for isolated tricuspid surgery ranges from approximately 5-10%, but can be significantly higher in patients who are referred late with advanced organ dysfunction.
- Earlier referral is better: A 2022 study published in the Journal of the American College of Cardiology found that earlier surgical intervention for isolated severe TR was associated with improved survival compared to prolonged medical management in patients with progressive symptoms.
If you are being monitored with "watchful waiting" for significant TR, it is reasonable to ask your physician what specific criteria they are using to determine when to refer you for surgery — and whether that timing aligns with current guideline recommendations.
How to Make the Right Decision About TR Repair Options
Choosing the right treatment path for tricuspid regurgitation requires answering several questions:
- Is your TR primary or secondary? Has the underlying cause been addressed?
- What is the severity — and is it progressing?
- How is your right ventricle functioning? Is there dilation or reduced function on imaging?
- Do you need surgery on another valve at the same time?
- What is your overall surgical risk, considering age, kidney function, liver function, prior surgeries, and frailty?
- Are you a candidate for repair, or will replacement be necessary?
- If you are high-risk, is a transcatheter option appropriate and available at a center with expertise?
These are not simple questions, and the answers require a surgeon who operates on tricuspid valves regularly and understands the nuances of right heart physiology. Tricuspid valve surgery is performed far less frequently than aortic or mitral procedures, which means expertise varies significantly from center to center.
You can learn more about how procedure volume affects outcomes in cardiac surgery on our education blog, and I encourage every patient to understand their personal risk profile before making a surgical decision. Our free cardiac surgery risk calculator is a helpful starting point.
Questions to Ask Your Surgeon
If you have been recommended for tricuspid valve surgery, consider asking:
- How many tricuspid valve surgeries do you perform per year?
- Do you anticipate repair or replacement, and why?
- What type of annuloplasty ring or prosthetic valve do you recommend?
- Am I a candidate for a catheter-based approach, and if not, why?
- What are the expected outcomes and risks specific to my case?
When a Second Opinion Changes the Plan
In my experience, tricuspid valve decisions are among the most frequently revised after an independent review. Common findings include:
- Patients told to "wait and see" who actually have guideline-based indications for intervention now.
- Patients recommended for tricuspid replacement who are actually candidates for repair.
- Patients undergoing left-sided valve surgery whose moderate TR and dilated annulus are not being addressed in the surgical plan.
- Patients offered open surgery who may be candidates for newer transcatheter approaches — or the reverse.
These are not minor differences. They can affect your recovery, your long-term heart function, and whether you face a reoperation years down the road.
If you are facing a decision about tricuspid regurgitation treatment — whether isolated or in combination with other valve surgery — a WhiteGloveMD second opinion can help you understand all of your options and ensure your surgical plan aligns with the latest evidence and guidelines. Our board-certified cardiac surgeon reviews your imaging, records, and clinical data personally and provides a detailed, written assessment. Start your review today and get the clarity you need before making one of the most important decisions of your life.